THE DEAL, AT A GLANCE
From the announcementRelay Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedRelay Therapeutics raised $400M Series DFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersRelay Therapeutics is financing a clinical-stage oncology strategy built around dynamic protein targeting, with the Series D proceeds framed around advancing RLY-2608…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Relay Therapeutics · Financing Record
Explore source-linked visual explanations for Relay Therapeutics. Unsupported claims are withheld while source review continues.
Record 453 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →